Fluid Quip Technologies (FQT), a global leader in the development and advancement of novel technologies and engineering solutions for the biofuels, beverage alcohol, and biochemical industries, ...

AceLink is advancing a small-molecule treatment option for Fabry disease, which could provide a more convenient alternative ...

AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...

This prospective case-control study included 85 patients with lung involvement related to the COVID-19 virus and a group of ...

Mineralys Therapeutics (MLYS) has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for ...

Obesity significantly impacts cardiovascular health, increasing risks such as left ventricular hypertrophy, atherosclerosis, and hypertension. Pharmac ...

Department of Chemistry, Indian Institute of Technology Kharagpur, Kharagpur 721302, India ...

One major source of reactive oxygen species is NOX2, an enzyme that becomes more active in people with obesity. NOX2 influences the activity of several key proteins that regulate the heart's rhythm.

However, when the researchers blocked an earlier step in glycolysis, the enzyme glucose-6-phosphate isomerase, this had no effect on the growth of the cancer cells.

Nat Med. 2005;11(2):118-119. The ACE enzyme, a target of blood pressure medications, now gains a new function in mice. The enzyme cleaves proteins linked to the cell membrane by GPI linkages ...